DIN 02451174 — UPTRAVI 600 MCG
UPTRAVI is a tablet of Selexipag marketed by JANSSEN INC. The full Selexipag monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02451174
- Brand name
- UPTRAVI
- Active ingredient
- Selexipag
- Strength
- 600 MCG
- Dosage form
- TABLET
- Route
- ORAL
- Manufacturer
- JANSSEN INC
- Health Canada status
- MARKETED
- Drug class
- Prostacyclin (IP) receptor agonist
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Selexipag products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02451190 | UPTRAVI | 1000 MCG | TABLET | JANSSEN INC | MARKETED |
| 02451204 | UPTRAVI | 1200 MCG | TABLET | JANSSEN INC | MARKETED |
| 02451212 | UPTRAVI | 1400 MCG | TABLET | JANSSEN INC | MARKETED |
| 02451220 | UPTRAVI | 1600 MCG | TABLET | JANSSEN INC | MARKETED |
| 02451158 | UPTRAVI | 200 MCG | TABLET | JANSSEN INC | MARKETED |
| 02451166 | UPTRAVI | 400 MCG | TABLET | JANSSEN INC | MARKETED |
| 02451182 | UPTRAVI | 800 MCG | TABLET | JANSSEN INC | MARKETED |